Shaun R. Bagai
Chief Executive Officer
Mr. Bagai brings more than 20 years of medical technology expertise with a proven track record in leadership roles in clinical research, sales, marketing and market development. He has launched new technologies into regional and global marketplaces in both large corporations and growth-phase novel technology companies. He was instrumental in developing the European market for renal denervation which led to the acquisition of the first renal denervation company, Ardian, Inc. by Medtronic in 2011. Most recently, Mr. Bagai led Global Market Development for HeartFlow, Inc. which included directing Japanese market research, regulatory/payer collaboration, and Key Opinion Leader development to create value resulting in a company investment to form HeartFlow-Japan. Prior to leaving HeartFlow, he also successfully orchestrated their largest clinical trial and contracted HeartFlow’s first global customers. Mr. Bagai is a graduate from the University of California, Santa Barbara with a B. Sc. In Biology/Pre-med.